On Jul. 11, 2022, the National Institute of Allergy and Infectious Diseases (NIAID) launched an early-stage clinical trial evaluating an investigational vaccine to prevent infection with Nipah virus. The experimental vaccine was manufactured by Moderna, and was developed in collaboration with NIAIDﾒs Vaccine Research Center.

It is based on a messenger RNA (mRNA) platformﾗa technology used in several approved COVID-19 vaccines. NIAID sponsored the Phase 1 clinical study, which is being conducted at the NIH Clinical Center in Bethesda, Maryland.